Copyright
©The Author(s) 2019.
World J Gastroenterol. May 7, 2019; 25(17): 2133-2143
Published online May 7, 2019. doi: 10.3748/wjg.v25.i17.2133
Published online May 7, 2019. doi: 10.3748/wjg.v25.i17.2133
Table 1 Patient cohort
| Patient | Female | Male | Age (yr) | Grading | Functionality | Resection (cm) | HBP | Others |
| 1 | X | 55 | G2 | yes, WD | IL, 62 + CC, 4 | X | ||
| 2 | X | 68 | G2 | yes, WD | IL, 40 | X | X | |
| 3 | X | 72 | G2 | yes, WD | IL, 56 + CO, 11 | X | X | |
| 4 | X | 79 | G1 | yes, WD | ileocecal | X | ||
| IL + jejunum, 150 | ||||||||
| 5 | X | 60 | G1 | yes, WD | hemicolectomy | X | X | |
| 6 | X | 65 | G2 | yes, WD | hemicolectomy | X | ||
| 7 | X | 47 | G2 | yes, WD | hemicolectomy, 220 | X | ||
| 8 | X | 77 | G1 | yes, WD | hemicolectomy, 120 | X | ||
| 9 | X | 43 | G2 | no, WD | no | X | ||
| 10 | X | 61 | G2 | MD, Serotonin | ileocecal, 40 | X | ||
| 11 | X | 73 | G1 | yes, WD | hemicolectomy, IL | X | ||
| 12 | X | 57 | G1 | yes, WD | mid IL | X | ||
| 13 | X | 63 | G2 | yes, WD | IL segments | X | X | |
| 14 | X | 48 | G2 | yes, WD | IL, 23 + CO, 31 | X | X | |
| 15 | X | 64 | G2 | yes, WD | IL, 70 | X | ||
| 16 | X | 77 | unknown | WD, Chromogranin | IL, 64 | X | ||
| 17 | X | 74 | G2 | yes, WD | IL, 18 | X | ||
| 18 | X | 78 | unknown | yes, WD | no | X | X | |
| 19 | X | 83 | G1 | Chromogranin | no | X | ||
| 20 | X | 39 | G1 | no, well diff. | no | X | X | |
| Total | 12 | 8 | ||||||
| Average age | 61.1 | 68.7 | 64.1 |
Table 2 Clinical parameters of the patients
| Patient | Nutricion | Somatostatin | Dosage | Interval | Loperamide1 | Disease | NET type | Primary | Metastases | in | PRRT | |||
| consultation | analog | stage | Liver | Lymph | Bone | Lung | Peritoneum | |||||||
| 1 | yes | OCT | 30 mg | 4 wk | if required | IV | functional | midgut | x | x | x | 2nd | ||
| 2 | yes | OCT | 20 mg | 4 wk | if required | IIIb | functional | midgut | x | x | x | 3rd | ||
| 3 | yes | OCT | 30 mg | 4 wk | no | IV | functional | midgut | x | x | x | x | 2nd | |
| 4 | yes | LAN | 120 mg | 6 wk | no | IV | functional | midgut | x | x | x | x | 2nd | |
| 5 | yes | LAN | 120 mg | 3 wk | no | IV | functional | midgut | x | x | 2nd | |||
| 6 | yes | OCT | 30 mg | 4 wk | no | IIIb | functional | midgut | x | x | 4th | |||
| 7 | yes | OCT | 30 mg | 4 wk | no | IIIb | functional | midgut | x | x | 3rd | |||
| 8 | yes | LAN | 120 mg | 4 wk | if required | IV | functional | midgut | x | x | 2nd | |||
| 9 | yes | no | no | IV | nonfunctional | pancreas | x | x | x | 1st | ||||
| 10 | yes | OCT | 30 mg | 4 wk | no | IV | functional | midgut | x | x | x | 3rd | ||
| OCT s.c. | + 100 µg | if required | ||||||||||||
| 11 | yes | OCT | 30 mg | 4 wk | no | IIIb | functional | midgut | x | x | 1st | |||
| 12 | yes | LAN | 120 mg | 4 wk | if required | IV | functional | midgut | x | 2nd | ||||
| 13 | yes | OCT | 30 mg | 4 wk | if required | IV | functional | midgut | x | 3rd | ||||
| 14 | yes | LAN | 120 mg | 4 wk | no | IV | functional | appendix | x | 2nd | ||||
| 15 | yes | OCT | 30 mg | 4 wk | no | IV | functional | midgut | x | x | x | 3rd | ||
| 16 | yes | OCT | 20 mg | 4 wk | if required | IV | functional | midgut | x | x | 2nd | |||
| 17 | yes | LAN | 120 mg | 4 wk | if required | IIIb | functional | midgut | x | x | x | 2nd | ||
| 18 | yes | OCT | 30 mg | 3 wk | if required | IV | functional | CUP | x | x | 3rd | |||
| 19 | yes | OCT | 30 mg | 4 wk | no | IV | nonfunctional | pancreas | x | x | x | 1st | ||
| 20 | yes | OCT | 30 mg | 4 wk | no | IV | functional | CUP | x | x | 3rd | |||
Table 3 Effect of Detoxsan® powder on the bowel movements as evaluated by patients
| Patient | Empirical evaluation of the patients | Intake time (d) | Dose (g/d) | Bowel movement | ||
| Satisfied | Uncertain | Non-satisfied | (frequency per day) | |||
| 1 | X | 41 | 4 x 5 | 9 to 12 | ||
| 2 | X | 10 | 6 x 3 | 8 to 11 | ||
| 3 | X | 160 | 1 x 3 | 1 to 3 | ||
| 4 | X | 118 | 3 x 3 | 2 to 3 | ||
| 5 | X | 201 | 3 x 3 | 3 to 5 | ||
| 6 | X | 106 | 3 x 3 | 1 to 3 | ||
| 7 | X | 215 | 2 x 2 | 3 | ||
| 8 | X | 605 | 2 x 2 | 1 to 3 | ||
| 9 | X | 21 | 3 x 1 | 1 to 2 | ||
| 10 | X | 134 | 2 x 2 | 3 to 5 | ||
| 11 | X | 220 | 3 x 1 | 2 to 3 | ||
| 12 | X | 427 | 2 x 3 | 2 to 3 | ||
| 13 | X | 138 | 2 x 2 | 1 to 2 | ||
| 14 | X | 31 | 2 x 3 | 2 to 4 | ||
| 15 | X | 21 | 1 x 3 | 1 to 2 | ||
| 16 | X | 31 | 1 x 5 | 1 | ||
| 17 | X | 20 | 2 x 3 | 6 to 7 | ||
| 18 | X | 62 | 2 x 3 | 3 to 4 | ||
| 19 | X | 31 | 1 x 3 | 1 to 2 | ||
| 20 | X | 31 | 2 x 3 | 1 to 3 | ||
| Total | 15 | 3 | 3 | |||
| Percentage | 70.0 | 15.0 | 15.0 | |||
Table 4 Diary of a 57-year-old male patient using Detoxsan® powder over 3 mo
| Detoxsan® powder intake (d) | days | Dose (g/d) | Bowel movements (frequency per day) | Empirical evaluation, daily | |
| Satisfied | Non-satisfied | ||||
| 1 to 2 | 2 x 2 | 5 to 8 | 2 | ||
| 3 to 8 | 2 x 2 | 1 to 4 | 6 | ||
| 9 to 11 | 2 x 2 | 5 to 8 | 3 | ||
| 12 to 13 | 2 x 3 | 5 to 8 | 2 | ||
| 14 to 26 | 2 x 2 | 1 to 4 | 13 | ||
| 27 to 28 | 2 x 2 | 5 to 8 | 2 | ||
| 29 to 31 | 2 x 2 | 1 to 4 | 3 | ||
| 32 to 43 | 2 x 3 | 1 to 4 | 12 | ||
| 44 to 49 | 2 x 3 | 5 to 8 | 6 | ||
| 50 to 75 | 2 x 3 | 1 to 4 | 26 | ||
| 76 to 79 | 2 x 3 | 5 to 8 | 4 | ||
| 80 to 87 | 2 x 3 | 1 to 4 | 8 | ||
| 88 to 91 | 2 x 3 | 5 to 8 | 4 | ||
| 92 to 120 | 2 x 3 | 1 to 4 | 28 | ||
| Sum of days | 96 | 23 | |||
Table 5 Blood parameters determined before (in brackets) and after the application of Detoxsan® powder
| Patient | Serotonin (µg/L) | Creatinine (µmol/L) | Urea (mmol/L) | Sodium (mmol/L) | Potassium (mmol/L) | Calcium (mmol/L) |
| 1 | (1.554) 2.442 | (58.0) 62.4 | (3.1) 2.7 | (139) 134 | (3.7) 5.2 | (2.3) 2.2 |
| 2 | (ND) 940 | (126.7) 142.3 | (5.5) 7.3 | (139) 142 | (4.0) 4.2 | (2.4) 2.4 |
| 3 | (289) 530 | (59.0) 69.8 | (4.1) 5.2 | (138) 133 | (4.9) 4.4 | (2.3) 2.2 |
| 4 | (919) 718 | (75.0) 92.1 | (4.0) 4.8 | (134) 140 | (3.9) 4.0 | (2.2) 2.3 |
| 5 | (1.834) 1.330 | (57.9) 91.9 | (4.4) 5.4 | (144) 145 | (4.2) 3.9 | (2.3) 2.3 |
| 6 | (398) 540 | (72.8) 91.8 | (7.8) 10.4 | (141) 137 | (4.3) 4.1 | (2.0) 2.1 |
| 7 | (ND) 318 | (53.0) 46.0 | (3.1) 3.1 | (139) 139 | (3.9) 3.4 | (2.3) 2.1 |
| 8 | (946) 399 | (167.5) 204.7 | (4.7) 9.9 | (142) 145 | (4.2) 5.0 | (2.3) 2.1 |
| 9 | (394) 575 | (73.2) 66.9 | (3,7) 5.1 | (136) 138 | (4.3) 4.4 | (2.3) 2.3 |
| 10 | (2.500) 688 | (60.5) 83.7 | (3.6) 3.8 | (146) 142 | (3.8) 4.5 | (2.3) 2.3 |
| 11 | (263) 1.939 | (59.3) 93.8 | (6.8) 6.5 | (144) 142 | (4.3) 4.2 | (2.1) 2.0 |
| 12 | (1.102) 1.025 | (85.6) 70,6 | (4.1) 3.4 | (143) 142 | (3.9) 3.2 | (2.2) 2.2 |
| 13 | (1.230) 708 | (70.0) 69.5 | (5.4) 3.5 | (144) 145 | (4.0) 4.3 | (2.4) 2.5 |
| 14 | (1.967) 775 | (46,9) 54,9 | (2.6) 3.2 | (142) 143 | (4.4) 4.3 | (2.3) 2.3 |
| 15 | (2.052) 2.500 | (75.1) 110.7 | (4.6) 6.3 | (137) 141 | (3.9) 3.8 | (2.3) 2.3 |
| 16 | (477) 353 | (58.6) 55.9 | (5.8) 7.0 | (144) 146 | (4.2) 4.8 | (2.2) 2.4 |
| 17 | (1.224) 1.446 | (50.3) 48.3 | (3.5) 3.9 | (143) 142 | (4.0) 4.0 | (2.3) 2.3 |
| 18 | (1.185) 2.500 | (52.7) 61.6 | (3.5) 3.4 | (143) 140 | (4.2) 4.3 | (2.3) 2.3 |
| 19 | 95 (63) | (155.0) 171.5 | (8.2) 13.9 | (133) 137 | (4.1) 4.6 | (2.3) 2.3 |
| 20 | 68 (64) | (75.5) 74.3 | (5.3) 5.8 | (144) 142 | (4.5) 4.1 | (2.4) 2.4 |
- Citation: Langbein T, Dathe W, Deuerling A, Baum RP. Efficacy of Detoxsan® powder on diarrhea caused by gastrointestinal neuroendocrine tumors. World J Gastroenterol 2019; 25(17): 2133-2143
- URL: https://www.wjgnet.com/1007-9327/full/v25/i17/2133.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i17.2133
